{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:09:49Z","timestamp":1780513789003,"version":"3.54.1"},"reference-count":36,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004488","name":"Croatian Science Foundation (Hrvatska Zaklada za Znanost) project \u201cGenetic and epigenetic markers as indicators of aggressiveness of differentiated thyroid cancer\u201d","doi-asserted-by":"publisher","award":["IP-2019-04-1130"],"award-info":[{"award-number":["IP-2019-04-1130"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Objectives: The response to radioiodine therapy (RAI) in differentiated thyroid cancer (DTC) patients is one of the most important factors that determines the treatment outcome and overall prognosis. The objective of this study is to determine the correlation between BRAFV600E and TERT promoter (TERTp) mutation in tumor samples of DTC patients with the response to RAI as well as correlation with clinical and pathohistological features. Methods: Samples of 110 DTC patients (80 with intermediate and high risk of disease recurrence-IHR and 30 with distant metastases) were analyzed for BRAFV600E and TERTp mutation (BRAF\/TERT) and 89 patients were assessed for the response to RAI. Results: Sixty-one (55.5%) patients had BRAFV600E mutation, 30 (27.3%) had TERTp mutation, while 21 (19.1%) patients had both mutations. In the IHR group, the study showed a statistically significant association between genotype BRAF\/TERTp and treatment outcome (p = 0.04). IHR DTC patients with BRAF-\/TERT- finding showed in general an excellent response to RAI, while patients with BRAF\/TERT co-mutation had a predominantly incomplete or indeterminate response. In DTC patients with BRAF\/TERT co-mutation that presented with distant metastases, a tendency to a higher frequency of RAI-refractory (RAI-R) disease was recorded, but without statistical significance. The pathohistological and clinical features that significantly correlated with BRAF\/TERT status are age at diagnosis, locoregional lymph node involvement, the largest positive lymph node diameter, tumor angioinvasion and the presence of distant metastases. Conclusions:\u00a0BRAF\/TERT co-mutation may be associated with a less favorable disease course and poorer response to RAI. However, findings in patients with distant metastases should be considered exploratory due to the limited sample size.<\/jats:p>","DOI":"10.3390\/genes17060645","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:58:38Z","timestamp":1780473518000},"page":"645","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Correlation Between the Presence of BRAFV600E and TERT Promoter Mutation and the Response to Treatment with Iodine 131 in Differentiated Thyroid Cancer Patients"],"prefix":"10.3390","volume":"17","author":[{"given":"Roko","family":"Grani\u0107","sequence":"first","affiliation":[{"name":"Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, 10 000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7665-0069","authenticated-orcid":false,"given":"Ivan","family":"Bla\u017eekovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, 10 000 Zagreb, Croatia"},{"name":"School of Medicine, Catholic University of Zagreb, 10 000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1734-0015","authenticated-orcid":false,"given":"Josipa","family":"Mi\u0161","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, University Hospital Center Sestre Milosrdnice, 10 000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5633-5745","authenticated-orcid":false,"given":"Ivan","family":"\u0160amija","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, University Hospital Center Sestre Milosrdnice, 10 000 Zagreb, Croatia"},{"name":"School of Dental Medicine, University of Zagreb, 10 000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8858-3524","authenticated-orcid":false,"given":"Tihana Regovi\u0107","family":"D\u017eombeta","sequence":"additional","affiliation":[{"name":"Department of Pathology Ljudevit Jurak, University Hospital Center Sestre Milosrdnice, 10 000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, 10 000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gorana","family":"Miro\u0161evi\u0107","sequence":"additional","affiliation":[{"name":"School of Dental Medicine, University of Zagreb, 10 000 Zagreb, Croatia"},{"name":"Department of Internal Medicine, University Hospital Center Sestre Milosrdnice, 10 000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Bakuni\u0107","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb, 10 000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4481-6365","authenticated-orcid":false,"given":"Kristina","family":"Kralik","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, 31 000 Osijek, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Fr\u00f6be","sequence":"additional","affiliation":[{"name":"Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, 10 000 Zagreb, Croatia"},{"name":"School of Dental Medicine, University of Zagreb, 10 000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvonko","family":"Kusi\u0107","sequence":"additional","affiliation":[{"name":"Croatian Academy of Sciences and Arts, 10 000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5631-164X","authenticated-orcid":false,"given":"Tomislav","family":"Juki\u0107","sequence":"additional","affiliation":[{"name":"Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, 10 000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, 10 000 Zagreb, Croatia"},{"name":"Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, 31 000 Osijek, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(22)00035-3","article-title":"The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020","volume":"10","author":"Pizzato","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_2","unstructured":"(2026, January 22). GLOBOCAN. Available online: https:\/\/gco.iarc.fr\/today\/."},{"key":"ref_3","unstructured":"Hrvatski Zavod za Javno Zdravstvo, and Registar za rak Republike Hrvatske (2026, January 15). Incidencija raka u Hrvatskoj u 2023. godini. Available online: https:\/\/www.hzjz.hr\/periodicne-publikacije\/incidencija-raka-u-hrvatskoj-u-2023-godini\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1001\/jama.2017.2719","article-title":"Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974\u20132013","volume":"317","author":"Lim","year":"2017","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"24855","DOI":"10.1038\/s41598-024-76613-5","article-title":"Impact of distant metastasis on overall survival and cancer specific survival of elderly patients with differentiated thyroid cancer","volume":"14","author":"Chen","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejso.2021.09.001","article-title":"Spinal metastases from thyroid cancer: Some prognostic factors","volume":"48","author":"Dubory","year":"2022","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1089\/thy.2013.0633","article-title":"Spinal metastases due to thyroid carcinoma: An analysis of 202 patients","volume":"24","author":"Kushchayeva","year":"2014","journal-title":"Thyroid"},{"key":"ref_8","first-page":"233","article-title":"Uncommon metastases from differentiated thyroid carcinoma","volume":"15","author":"Song","year":"2012","journal-title":"Hell. J. Nucl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Juki\u0107, T., Bla\u017eekovi\u0107, I., Franceschi, M., Ov\u010dari\u010dek Petranovi\u0107, P., Butkovi\u0107, M.B., Dabeli\u0107, N., Grani\u0107, R., Punda, M., Sonicki, Z., and Vagi\u0107, D. (2022). Long-term outcome of differentiated thyroid cancer patients\u2014Fifty years of Croatian thyroid disease referral centre experience. Diagnostics, 12.","DOI":"10.3390\/diagnostics12040866"},{"key":"ref_10","first-page":"1368","article-title":"Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance","volume":"72","author":"Huize","year":"2024","journal-title":"Drug Resist. Updates"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1530\/EJE-20-1073","article-title":"Impact of age on survival in radioiodine refractory differentiated thyroid cancer patients","volume":"184","author":"Saie","year":"2021","journal-title":"Eur. J. Endocrinol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s12094-025-04122-6","article-title":"Clinical and treatment patterns of advanced and radioiodine-refractory differentiated thyroid cancer. ERUDIT study","volume":"28","author":"Sambo","year":"2025","journal-title":"Clin. Transl. Oncol."},{"key":"ref_15","first-page":"e250225","article-title":"BRAF V600E in thyroid cancer: Navigating prognostic uncertainty and therapeutic opportunity","volume":"14","year":"2025","journal-title":"Eur. Thyroid J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jnci\/95.8.625","article-title":"BRAF mutation in papillary thyroid carcinoma","volume":"95","author":"Cohen","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"27","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41571-023-00852-0","article-title":"BRAF\u2014A tumour-agnostic drug target with lineage-specific dependencies","volume":"21","author":"Hanrahan","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.eprac.2025.12.003","article-title":"Prognostic Value of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis of Nodal Involvement, Distant Metastases, Recurrence, and Mortality","volume":"32","author":"Gatta","year":"2025","journal-title":"Endocr. Pract."},{"key":"ref_20","first-page":"661","article-title":"Germline Polymorphisms of the VEGF Pathway Predict Recurrence in Nonadvanced Differentiated Thyroid Cancer","volume":"102","author":"Marotta","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s00259-024-06991-5","article-title":"Radioiodine-refractory thyroid cancer\u2014Is it time to change the definition in light of novel redifferentiation therapies?","volume":"52","author":"Kreissl","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Dratwa, M., Wysocza\u0144ska, B., \u0141acina, P., Kubik, T., and Bogunia-Kubik, K. (2020). TERT-Regulation and Roles in Cancer Formation. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.589929"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3803\/EnM.2022.1477","article-title":"Frequency of TERT Promoter Mutations in Real-World Analysis of 2092 Thyroid Carcinoma Patients","volume":"37","author":"Yang","year":"2022","journal-title":"Endocrinol. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s12020-019-02117-2","article-title":"Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: A systematic review and meta-analysis","volume":"67","author":"Yang","year":"2020","journal-title":"Endocrine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e44540","DOI":"10.1097\/MD.0000000000044540","article-title":"Prognostic significance of BRAF V600E and TERT promoter mutations in radioiodine resistance and recurrence of differentiated thyroid cancer","volume":"104","author":"Nhung","year":"2025","journal-title":"Medicine"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Steinberg, E., Dimitstein, O., Morand, G.B., Forest, V.-I., da Silva, S.D., Pusztaszeri, M., Alohali, S., and Payne, R.J. (2024). Clinical and histopathological features of thyroid cancer with TERT promoter molecular alterations in isolation versus with concurrent molecular alterations: A multicenter retrospective study. Cancers, 16.","DOI":"10.3390\/cancers16203446"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1210\/jc.2016-2785","article-title":"TERT, BRAF and NRAS in primary thyroid cancer and metastatic disease","volume":"102","author":"Melo","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"23719","DOI":"10.1038\/s41598-024-75087-9","article-title":"TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer","volume":"14","author":"Tan","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/cen.14316","article-title":"The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta-analysis","volume":"94","author":"Chen","year":"2021","journal-title":"Clin. Endocrinol."},{"key":"ref_30","first-page":"50","article-title":"Mutations of the TERT promoter are associated with aggressiveness and recurrence\/distant metastasis of papillary thyroid carcinoma","volume":"20","author":"Liu","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2147\/CMAR.S159583","article-title":"Co-existence of BRAFV600E and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis","volume":"10","author":"Ren","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12022-024-09836-x","article-title":"Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management","volume":"35","author":"Mete","year":"2024","journal-title":"Endocr. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Pacini","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s12022-025-09859-y","article-title":"Prevalence and Clinical Impact of BRAF p.V600E Mutation in Papillary Thyroid Carcinoma","volume":"36","author":"Brumfield","year":"2025","journal-title":"Endocr. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Blazekovic, I., Samija, I., Perisa, J., Gall Troselj, K., Regovic Dzombeta, T., Radulovic, P., Romic, M., Granic, R., Sisko Markos, I., and Frobe, A. (2024). Association of BRAF V600E mutant allele proportion with the dissemination stage of papillary thyroid cancer. Biomedicines, 12.","DOI":"10.3390\/biomedicines12030477"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"103945","DOI":"10.1016\/j.clon.2025.103945","article-title":"The BRAFV600E Mutation Enhances Age-Based Prognostic Stratification in Radioiodine-Treated Papillary Thyroid Cancer: A Retrospective Cohort Study","volume":"48","author":"Cao","year":"2025","journal-title":"Clin. Oncol."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/6\/645\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:19:04Z","timestamp":1780510744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/6\/645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["genes17060645"],"URL":"https:\/\/doi.org\/10.3390\/genes17060645","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,31]]}}}